NASDAQ$XERS
Xeris Biopharma Holdings Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Xeris Biopharma reported a net product revenue increase and launched Recorlev and Gvoke Kit.
Xeris Biopharma reported a strong first quarter with a 33% increase in net product revenue on a pro forma basis, driven by higher sales of Gvoke, Keveyis, and the launch of Recorlev. The company ended the quarter with $132.1 million in cash and cash equivalents and affirmed its 2022 revenue and year-end cash guidance.
- Net product revenue increased by 172% compared to the same period in 2021, reaching $21.9 million.
- Gvoke prescriptions topped 30,000, growing more than 88% compared to Q1 2021.
- Launched Recorlev and Gvoke Kit during the quarter.
- Ended Q1 with $132.1 million in cash, cash equivalents and short-term investments.
Headline financials
Revenue & EPS history
Xeris Biopharma · Revenue · Quarterly
$22.1M
Revenue by segment
Xeris Biopharma · $65.7M total across 3 segments · Q1 2022
- Recorlev$21.9M—33.3%
- Gvoke$21.9M—33.3%
- Keveyis$21.9M—33.3%
Forward guidance
Xeris Biopharma is affirming its 2022 guidance for combined net product revenues of $105M - $120M, $50M in synergies, 2022 year-end cash balance of $90M-$110M, and cash flow breakeven by year-end 2023.
Tailwinds
- Affirms 2022 revenue guidance of $105M - $120M
- Expects $50M in synergies in 2022
- Anticipates year-end cash balance of $90M - $110M
- Projects cash flow breakeven by year-end 2023
- Additional $50.0 million will be available for the Company to draw until March 2023.
Headwinds
- Reliance on third-party suppliers for products
- Risks associated with regulatory approval of product candidates
- Ability to effectively market and sell products
- Failure to realize expected benefits of Strongbridge Biopharma acquisition
- Impact of the ongoing COVID-19 pandemic
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+4.5%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+33.5%
Q1 2020
Best reaction
-21.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | -1.9% | -3.1% | |
| Q4 2025 | -2.0% | -5.1% | -1.3% | |
| Q3 2025 | -21.8% | -24.6% | -34.0% | |
| Q1 2025 | +15.2% | +9.4% | +2.2% | |
| Q4 2024 | +9.5% | +16.4% | +17.0% | |
| Q3 2024 | -2.4% | -6.2% | +9.2% | |
| Q2 2024 | +8.9% | +19.2% | +17.8% | |
| Q1 2024 | -4.9% | +2.7% | +25.9% | |
| Q4 2023 | -20.8% | -26.9% | -33.8% | |
| Q3 2023 | -14.9% | -21.2% | +2.5% | |
| Q2 2023 | -5.6% | -8.4% | -14.1% | |
| Q1 2023 | +22.1% | +20.8% | +22.9% | |
| Q4 2022 | -18.3% | -20.9% | +23.5% | |
| Q3 2022 | +0.0% | -5.3% | -3.3% | |
| Q2 2022 | +7.1% | +11.2% | +7.1% | |
| Q1 2022 | -15.1% | +23.5% | +5.6% | |
| Q4 2021 | +9.3% | +8.1% | -4.5% | |
| Q3 2021 | +6.1% | +26.5% | +13.3% | |
| Q2 2021 | -18.9% | -18.9% | -4.6% | |
| Q1 2021 | +3.3% | +7.8% | +18.6% | |
| Q4 2020 | -8.1% | +1.9% | -9.7% | |
| Q3 2020 | -0.9% | -3.1% | -26.1% | |
| Q2 2020 | -1.8% | +25.1% | +43.6% | |
| Q1 2020 | +33.5% | +62.8% | +100.0% | |
| Q4 2019 | -10.9% | -21.9% | -2.5% | |
| Q3 2019 | -10.1% | -8.2% | -1.9% | |
| Q2 2019 | -1.4% | +5.9% | +5.9% | |
| Q1 2019 | +13.3% | +13.3% | -22.8% | |
| Q4 2018 | -5.8% | -10.4% | -6.2% | |
| Q3 2018 | +5.8% | -9.3% | -13.0% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro